Viatris (XSWX:VTRS) Total Operating Expense: CHF3,806 Mil (TTM As of Mar. 2026)


XSWX:VTRS Viatris Inc XSWX:VTRS
60 GF Score
Price CHF13.06
GF Value CHF8.89
! 8 Warning Signs
View Full Analysis

What is Viatris Total Operating Expense?

Viatris XSWX:VTRS +0.62% 60 Total Operating Expense is CHF3,806 Mil as of Mar. 2026. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.89. The stock has 8 warning signs investors should review.

Viatris's Total Operating Expense for the three months ended in Mar. 2026 was CHF927 Mil. Viatris's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF3,806 Mil.

Viatris Total Operating Expense Related Terms

Viatris Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Viatris's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Total Operating Expense Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,798.59 4,510.16 4,216.07 4,380.70 3,793.24

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,033.90 933.15 905.17 1,040.27 926.97
XSWX:VTRS
60GF Score
Viatris Inc XSWX:VTRS
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF3,806 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of CHF3,806 Mil mean?
Viatris (XSWX:VTRS) has a Total Operating Expense of CHF3,806 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Viatris and its competitors.
Is Viatris' Total Operating Expense too high?
Viatris' current Total Operating Expense is CHF3,806 Mil. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' Total Operating Expense compare to NBIX and UTHR?
Viatris' Total Operating Expense of CHF3,806 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Viatris and its competitors. Viatris's current Total Operating Expense is CHF3,806 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current Total Operating Expense of CHF3,806 Mil. The stock's GF Value™ is CHF8.89, compared to a current price of CHF13.06 — trading 46.9% above its estimated fair value. The current Total Operating Expense is CHF3,806 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current Total Operating Expense is CHF3,806 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (XSWX:VTRS) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of CHF13.06 is trading 46.9% above its estimated GF Value™ of CHF8.89.

Key valuation signals for XSWX:VTRS:

  • Total Operating Expense: CHF3,806 Mil
  • GF Value™: CHF8.89 vs. price of CHF13.06 (46.9% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for XSWX:VTRS

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF13.06
Price
CHF8.89
GF Value